The absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with Cryptococcus neoformans

Journal of Immunology

Volumn 184, Issue 10, 2010, Pages 5755-5767

  Subramaniam, Krishanthi S ^a   Datta, Kausik ^a,b   Quintero, Eric ^c   Manix, Catherine ^a   Marks, Matthew S ^a   Pirofski, Liise Anne ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5A; IMMUNOGLOBULIN M; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; BACTERIUM ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; COLONY FORMING UNIT; CONTROLLED STUDY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS NEOFORMANS; CYTOKINE PRODUCTION; DISEASE SEVERITY; IMMUNOGLOBULIN PRODUCTION; INFECTION RESISTANCE; INFECTION SENSITIVITY; INFLAMMATION; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PULMONARY CRYPTOCOCCOSIS; SURVIVAL; TH1 CELL; ANIMAL; BLOOD; C57BL MOUSE; COMPARATIVE STUDY; CRYPTOCOCCOSIS; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; LUNG; LUNG MYCOSIS; METABOLISM; MICROBIOLOGY; MOUSE MUTANT; PATHOLOGY; UPREGULATION;

ANIMALS; ANTIBODIES, BACTERIAL; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; GENETIC PREDISPOSITION TO DISEASE; IMMUNOGLOBULIN M; LUNG; LUNG DISEASES, FUNGAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; UP-REGULATION;

EID: 77954751602     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901638     Document Type: Article

References (85)

1. Goldman, D. L., H. Khine, J. Abadi, D. L. Lindenberg, L. Pirofski, R. Niang, and A. Casadevall. 2001. Serologic Evidence for Cryptococcus neoformans Infection in Early Childhood. Pediatrics. 107: e66.
2. Abadi, J., and L. Pirofski. 1999. Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without HIV infection. J. Infect. Dis. 180: 915-919.
3. Datta, K., and L. Pirofski. 2006. Towards a vaccine for Cryptococcus neoformans: principles and caveats. FEMS. Yeast Res. 6: 525-536.
4. Casadevall, A., and J. R. Perfect. 1998. Human cryptococcosis. In Cryptococcus neoformans, 1st Ed. American Society of Microbiology, Washington, D.C., p. 407-457.
5. Garcia-Hermoso, D., G. Janbon, and F. Dromer. 1999. Epidemiological evidence for dormant Cryptococcus neoformans infection. J. Clin. Microbiol. 37: 3204-3209.
6. Huffnagle, G. B., M. F. Lipscomb, J. A. Lovchik, K. A. Hoag, and N. E. Street. 1994. The role of CD4+ and CD8+ T cells in the protective inflammatory response to a pulmonary cryptococcal infection. J. Leukoc. Biol. 55: 35-42.
7. Rivera, J., O. Zaragoza, and A. Casadevall. 2005. Antibody-mediated protection against Cryptococcus neoformans is dependent on B cells. Infect. Immun. 73: 1141-1150.
8. Ghosn, E. E., M. Russo, and S. R. Almeida. 2006. Nitric oxide-dependent killing of Cryptococcus neoformans by B-1-derived mononuclear phagocyte. J. Leukoc. Biol. 80: 36-44.
9. Almeida, S. R., L. S. Aroeira, E. Frymuller, M. A. Dias, C. S. Bogsan, J. D. Lopes, and M. Mariano. 2001. Mouse B-1 cell-derived mononuclear phagocyte, a novel cellular component of acute non-specific inflammatory exudate. Int. Immunol. 13: 1193-1201.
10. Casadevall, A., and L. A. Pirofski. 2003. Antibody-mediated regulation of cellular immunity and the inflammatory response. Trends Immunol. 24: 474-478. (Pubitemid 37088149)
11. Subramaniam, K., B. Metzger, L. H. Hanau, A. Guh, L. Rucker, S. Badri, and L. A. Pirofski. 2009. IgM(+) memory B cell expression predicts HIV-associated cryptococcosis status. J. Infect. Dis. 200: 244-251.
12. Subramaniam, K., N. French, and L. A. Pirofski. 2005. Cryptococcus neoformans-reactive and total immunoglobulin profiles of human immunodeficiency virusinfected and uninfected Ugandans. Clin. Diagn. Lab. Immunol. 12: 1168-1176.
13. Jalali, Z., L. Ng, N. Singh, and L. A. Pirofski. 2006. Antibody response to Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan in patients after solid-organ transplantation. Clin. Vaccine Immunol. 13: 740-746.
14. Carsetti, R., M. M. Rosado, and H. Wardmann. 2004. Peripheral development of B cells in mouse and man. Immunol. Rev. 197: 179-191.
15. Baumgarth, N., J. W. Tung, and L. A. Herzenberg. 2005. Inherent specificities in natural antibodies: a key to immune defense against pathogen invasion. Springer Semin. Immunopathol. 26: 347-362.
16. Hardy, R. R. 2006. B-1 B cell development. J. Immunol. 177: 2749-2754.
17. Feldmesser, M., A. Mednick, and A. Casadevall. 2002. Antibody-mediated protection in murine Cryptococcus neoformans infection is associated with pleotrophic effects on cytokine and leukocyte responses. Infect. Immun. 70: 1571-1580.
18. Mukherjee, J., M. D. Scharff, and A. Casadevall. 1992. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect. Immun. 60: 4534-4541.
19. Nakouzi, A., P. Valadon, J. D. Nosanchuk, N. Green, and A. Casadevall. 2001. Molecular basis for immunoglobulin M specificity to epitopes in Cryptococcus neoformans polysaccharide that elicit protective and nonprotective antibodies. Infect. Immun. 69: 3398-3409.
20. Fleuridor, R., Z. Zhong, and L. Pirofski. 1998. A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis. J. Infect. Dis. 178: 1213-1216.
21. Maitta, R., K. Datta, Q. Chang, R. Luo, K. Subramaniam, B. Witover, and L. Pirofski. 2004. Protective and non-protective human IgM monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificity and gene use. Infect. Immun. 72: 4810-4818.
22. Subramaniam, K. S., K. Datta, M. S. Marks, and L. A. Pirofski. 2009. Improved survival of mice deficient in secretory IgM following systemic infection with Cryptococcus neoformans. Infect. Immun. 78: 441-452.
23. Houpt, D. C., G. S. Pfrommer, B. J. Young, T. A. Larson, and T. R. Kozel. 1994. Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan. Infect. Immun. 62: 2857-2864.
24. Fleuridor, R., R. H. Lyles, and L. Pirofski. 1999. Quantitative and qualitative differences in the serum antibody profiles of HIV-infected persons with and without Cryptococcus neoformans meningitis. J. Infect. Dis. 180: 1526-1536.
25. Deshaw, M., and L. A. Pirofski. 1995. Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV- individuals. Clin. Exp. Immunol. 99: 425-432.
26. Boes, M., C. Esau, M. B. Fischer, T. Schmidt, M. Carroll, and J. Chen. 1998. Enhanced B-1 cell development, but impaired IgG antibody responses in mice deficient in secreted IgM. J. Immunol. 160: 4776-4787.
27. Rivera, J., J. Mukherjee, L. M. Weiss, and A. Casadevall. 2002. Antibody efficacy in murine pulmonary Cryptococcus neoformans infection: a role for nitric oxide. J. Immunol. 168: 3419-3427.
28. Datta, K., A. Lees, and L. A. Pirofski. 2008. Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan. Clin. Vaccine Immunol. 15: 1176-1187.
29. Marks, M., T. Burns, M. Abadi, B. Seyoum, J. Thornton, E. Tuomanen, and L. A. Pirofski. 2007. Influence of neutropenia on the course of serotype 8 pneumococcal pneumonia in mice. Infect. Immun. 75: 1586-1597.
30. Zaragoza, O., M. Alvarez, A. Telzak, J. Rivera, and A. Casadevall. 2007. The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response. Infect. Immun. 75: 2729-2739.
31. Jayasekera, J. P., E. A. Moseman, and M. C. Carroll. 2007. Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. J. Virol. 81: 3487-3494.
32. Hill, J. O., and P. L. Dunn. 1993. A T cell-independent protective host response against Cryptococcus neoformans expressed at the primary site of infection in the lung. Infect. Immun. 61: 5302-5308.
33. Goldman, D. L., J. Davis, F. Bommarito, X. Shao, and A. Casadevall. 2006. Enhanced allergic inflammation and airway responsiveness in rats with chronic Cryptococcus neoformans infection: potential role for fungal pulmonary infection in the pathogenesis of asthma. J. Infect. Dis. 193: 1178-1186.
34. Müller, U., W. Stenzel, G. Köhler, C. Werner, T. Polte, G. Hansen, N. Schütze, R. K. Straubinger, M. Blessing, A. N. McKenzie, et al. 2007. IL-13 induces disease-promoting type 2 cytokines, alternatively activated macrophages and allergic inflammation during pulmonary infection of mice with Cryptococcus neoformans. J. Immunol. 179: 5367-5377.
35. Herring, A. C., J. Lee, R. A. McDonald, G. B. Toews, and G. B. Huffnagle. 2002. Induction of interleukin-12 and gamma interferon requires tumor necrosis factor alpha for protective T1-cell-mediated immunity to pulmonary Cryptococcus neoformans infection. Infect. Immun. 70: 2959-2964.
36. Hoag, K. A., N. E. Street, G. B. Huffnagle, and M. F. Lipscomb. 1995. Early cytokine production in pulmonary Cryptococcus neoformans infections distinguishes susceptible and resistant mice. Am. J. Respir. Cell Mol. Biol. 13: 487-495.
37. Guillot, L., S. F. Carroll, R. Homer, and S. T. Qureshi. 2008. Enhanced innate immune responsiveness to pulmonary Cryptococcus neoformans infection is associated with resistance to progressive infection. Infect. Immun. 76: 4745-4756.
38. Hawlisch, H., Y. Belkaid, R. Baelder, D. Hildeman, C. Gerard, and J. Köhl. 2005. C5a negatively regulates toll-like receptor 4-induced immune responses. Immunity 22: 415-426. (Pubitemid 40545108)
39. Fang, C., X. Zhang, T. Miwa, and W. C. Song. 2009. Complement promotes the development of inflammatory T-helper 17 cells through synergistic interaction with Toll-like receptor signaling and interleukin-6 production. Blood 114: 1005-1015.
40. Tsuji, R. F., I. Kawikova, R. Ramabhadran, M. Akahira-Azuma, D. Taub, T. E. Hugli, C. Gerard, and P. W. Askenase. 2000. Early local generation of C5a initiates the elicitation of contact sensitivity by leading to early T cell recruitment. J. Immunol. 165: 1588-1598.
41. Guo, R. F., and P. A. Ward. 2005. Role of C5a in inflammatory responses. Annu. Rev. Immunol. 23: 821-852.
42. Alugupalli, K. R., R. M. Gerstein, J. Chen, E. Szomolanyi-Tsuda, R. T. Woodland, and J. M. Leong. 2003. The resolution of relapsing fever borreliosis requires IgM and is concurrent with expansion of B1b lymphocytes. J. Immunol. 170: 3819-3827.
43. Boes, M., A. P. Prodeus, T. Schmidt, M. C. Carroll, and J. Chen. 1998. A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J. Exp. Med. 188: 2381-2386.
44. Brown, J. S., T. Hussell, S. M. Gilliland, D. W. Holden, J. C. Paton, M. R. Ehrenstein, M. J. Walport, and M. Botto. 2002. The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae. Proc. Natl. Acad. Sci. USA 99: 16969-16974.
45. Diamond, M. S., B. Shrestha, A. Marri, D. Mahan, and M. Engle. 2003. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J. Virol. 77: 2578-2586.
46. Choi, Y. S., and N. Baumgarth. 2008. Dual role for B-1a cells in immunity to influenza virus infection. J. Exp. Med. 205: 3053-3064.
47. Rajan, B., T. Ramalingam, and T. V. Rajan. 2005. Critical role for IgM in host protection in experimental filarial infection. J. Immunol. 175: 1827-1833.
48. Kleinschek, M. A., U. Muller, S. J. Brodie, W. Stenzel, G. Kohler, W. M. Blumenschein, R. K. Straubinger, T. McClanahan, R. A. Kastelein, and G. Alber. 2006. IL-23 enhances the inflammatory cell response in Cryptococcus neoformans infection and induces a cytokine pattern distinct from IL-12. J. Immunol. 176: 1098-1106.
49. Haas, K. M., J. C. Poe, D. A. Steeber, and T. F. Tedder. 2005. B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity 23: 7-18.
50. Baumgarth, N., O. C. Herman, G. C. Jager, L. E. Brown, L. A. Herzenberg, and J. Chen. 2000. B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. J. Exp. Med. 192: 271-280.
51. Sundstrom, J. B., and R. Cherniak. 1992. The glucuronoxylomannan of Cryptococcus neoformans serotype A is a type 2 T-cell-independent antigen. Infect. Immun. 60: 4080-4087.
52. Rodrigues, M. L., L. Nimrichter, D. L. Oliveira, S. Frases, K. Miranda, O. Zaragoza, M. Alvarez, A. Nakouzi, M. Feldmesser, and A. Casadevall. 2007. Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport. Eukaryot. Cell 6: 48-59.
53. Rachini, A., D. Pietrella, P. Lupo, A. Torosantucci, P. Chiani, C. Bromuro, C. Proietti, F. Bistoni, A. Cassone, and A. Vecchiarelli. 2007. An anti-betaglucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect. Immun. 75: 5085-5094.
54. Wang, H., and S. H. Clarke. 2004. Positive selection focuses the VH12 B-cell repertoire towards a single B1 specificity with survival function. Immunol. Rev. 197: 51-59.
55. Baumgarth, N., O. C. Herman, G. C. Jager, L. Brown, L. A. Herzenberg, and L. A. Herzenberg. 1999. Innate and acquired humoral immunities to influenza virus are mediated by distinct arms of the immune system. Proc. Natl. Acad. Sci. USA 96: 2250-2255.
56. Tsuji, R. F., M. Szczepanik, I. Kawikova, V. Paliwal, R. A. Campos, A. Itakura, M. Akahira-Azuma, N. Baumgarth, L. A. Herzenberg, and P. W. Askenase. 2002. B cell-dependent T cell responses: IgM antibodies are required to elicit contact sensitivity. J. Exp. Med. 196: 1277-1290.
57. Shapiro, S., D. O. Beenhouwer, M. Feldmesser, C. Taborda, M. C. Carroll, A. Casadevall, and M. D. Scharff. 2002. Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3. Infect. Immun. 70: 2598-2604.
58. Shi, Y., T. Yamazaki, Y. Okubo, Y. Uehara, K. Sugane, and K. Agematsu. 2005. Regulation of aged humoral immune defense against pneumococcal bacteria by IgM memory B cell. J. Immunol. 175: 3262-3267.
59. Hart, M., A. Steel, S. A. Clark, G. Moyle, M. Nelson, D. C. Henderson, R. Wilson, F. Gotch, B. Gazzard, and P. Kelleher. 2007. Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease. J. Immunol. 178: 8212-8220.
60. Clutterbuck, E. A., S. Oh, M. Hamaluba, S. Westcar, P. C. Beverley, and A. J. Pollard. 2008. Serotype-specific and age-dependent generation of pneumococcal polysaccharide-specific memory B-cell and antibody responses to immunization with a pneumococcal conjugate vaccine. Clin. Vaccine Immunol. 15: 182-193.
61. Kruetzmann, S., M. M. Rosado, H. Weber, U. Germing, O. Tournilhac, H. H. Peter, R. Berner, A. Peters, T. Boehm, A. Plebani, et al. 2003. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J. Exp. Med. 197: 939-945.
62. Popi, A. F., D. S. Zamboni, R. A. Mortara, and M. Mariano. 2009. Microbicidal property of B1 cell derived mononuclear phagocyte. Immunobiology 214: 664-673.
63. Popi, A. F., J. D. Lopes, and M. Mariano. 2004. Interleukin-10 secreted by B-1 cells modulates the phagocytic activity of murine macrophages in vitro. Immunology 113: 348-354.
64. O'Garra, A., and M. Howard. 1992. IL-10 production by CD5 B cells. Ann. N. Y. Acad. Sci. 651: 182-199.
65. O'Garra, A., R. Chang, N. Go, R. Hastings, G. Haughton, and M. Howard. 1992. Ly-1 B (B-1) cells are the main source of B cell-derived interleukin 10. Eur. J. Immunol. 22: 711-717.
66. Charlier, C., K. Nielsen, S. Daou, M. Brigitte, F. Chretien, and F. Dromer. 2009. Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect. Immun. 77: 120-127.
67. Shao, X., A. Mednick, M. Alvarez, N. van Rooijen, A. Casadevall, and D. L. Goldman. 2005. An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. J. Immunol. 175: 3244-3251.
68. Kechichian, T. B., J. Shea, and M. Del Poeta. 2007. Depletion of alveolar macrophages decreases the dissemination of a glucosylceramide-deficient mutant of Cryptococcus neoformans in immunodeficient mice. Infect. Immun. 75: 4792-4798.
69. Guerrero, A., N. Jain, X. Wang, and B. C. Fries. 2010. Cryptococcus neoformans variants generated by phenotypic switching differ in virulence through effects on macrophage activation. Infect. Immun.78: 1049-1057.
70. Shea, J. M., T. B. Kechichian, C. Luberto, and M. Del Poeta. 2006. The cryptococcal enzyme inositol phosphosphingolipid-phospholipase C confers resistance to the antifungal effects of macrophages and promotes fungal dissemination to the central nervous system. Infect. Immun. 74: 5977-5988.
71. Hardison, S. E., S. Ravi, K. L. Wozniak, M. L. Young, M. A. Olszewski, and F. L. Wormley, Jr. 2010. Pulmonary infection with an interferon-{gamma}- producing Cryptococcus neoformans strain results in classical macrophage activation and protection. Am. J. Pathol. 176: 774-785.
72. Voelz, K., D. A. Lammas, and R. C. May. 2009. Cytokine signaling regulates the outcome of intracellular macrophage parasitism by Cryptococcus neoformans. Infect. Immun. 77: 3450-3457.
73. Zhang, Y., F. Wang, K. C. Tompkins, A. McNamara, A. V. Jain, B. B. Moore, G. B. Toews, G. B. Huffnagle, and M. A. Olszewski. 2009. Robust Th1 and Th17 immunity supports pulmonary clearance but cannot prevent systemic dissemination of highly virulent Cryptococcus neoformans H99. Am. J. Pathol. 175: 2489-2500.
74. Chang, Y. C., M. F. Stins, M. J. McCaffery, G. F. Miller, D. R. Pare, T. Dam, M. Paul-Satyaseela, K. S. Kim, K. J. Kwon-Chung, and M. Paul-Satyasee. 2004. Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier. Infect. Immun. 72: 4985-4995.
75. Hill, J. O. 1992. CD4+ T cells cause multinucleated giant cells to form around Cryptococcus neoformans and confine the yeast within the primary site of infection in the respiratory tract. J. Exp. Med. 175: 1685-1695.
76. Luberto, C., B. Martinez-Mariño, D. Taraskiewicz, B. Bolaños, P. Chitano, D. L. Toffaletti, G. M. Cox, J. R. Perfect, Y. A. Hannun, E. Balish, and M. Del Poeta. 2003. Identification of App1 as a regulator of phagocytosis and virulence of Cryptococcus neoformans. J. Clin. Invest. 112: 1080-1094.
77. Dromer, F., C. Bernede-Bauduin, D. Guillemot, O. Lortholary, and French Cryptococcosis Study Group. 2008. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS One 3: e2870.
78. Huber-Lang, M., J. V. Sarma, F. S. Zetoune, D. Rittirsch, T. A. Neff, S. R. McGuire, J. D. Lambris, R. L. Warner, M. A. Flierl, L. M. Hoesel, et al. 2006. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 12: 682-687.
79. Banda, N. K., B. Levitt, A. K. Wood, K. Takahashi, G. L. Stahl, V. M. Holers, and W. P. Arend. 2010. Complement activation pathways in murine immune complex-induced arthritis and in C3a and C5a generation in vitro. Clin. Exp. Immunol. 159: 100-108.
80. Dromer, F., C. Perronne, J. Barge, J. L. Vilde, and P. Yeni. 1989. Role of IgG and complement component C5 in the initial course of experimental cryptococcosis. Clin. Exp. Immunol. 78: 412-417.
81. Rhodes, J. C. 1985. Contribution of complement component C5 to the pathogenesis of experimental murine cryptococcosis. Sabouraudia 23: 225-234.
82. Jacob, A., B. Hack, E. Chiang, J. G. Garcia, R. J. Quigg, and J. J. Alexander. 2010. C5a alters blood-brain barrier integrity in experimental lupus. FASEB J. doi: 10.1096/fj.09-138834.
83. Kebir, H., K. Kreymborg, I. Ifergan, A. Dodelet-Devillers, R. Cayrol, M. Bernard, F. Giuliani, N. Arbour, B. Becher, and A. Prat. 2007. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 13: 1173-1175.
84. Uicker, W. C., H. A. Doyle, J. P. McCracken, M. Langlois, and K. L. Buchanan. 2005. Cytokine and chemokine expression in the central nervous system associated with protective cell-mediated immunity against Cryptococcus neoformans. Med. Mycol. 43: 27-38.
85. Köhl, J., R. Baelder, I. P. Lewkowich, M. K. Pandey, H. Hawlisch, L. Wang, J. Best, N. S. Herman, A. A. Sproles, J. Zwirner, et al. 2006. A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. J. Clin. Invest. 116: 783-796.